Paulo H M Chaves1, Bimal Ashar, Jack M Guralnik, Linda P Fried. 1. Division of Internal Medicine, Department of Medicine, School of Public Health, The Johns Hopkins University, Baltimore, Maryland, USA. pchaves@jhsph.edu
Abstract
OBJECTIVES: The World Health Organization (WHO) and other currently used criteria for defining anemia in older women are mainly based on statistical distribution considerations. To explore their clinical appropriateness, we evaluated the relationship between hemoglobin (Hb) concentration, prevalent mobility difficulty, and the Summary Performance Score (SPS). DESIGN: Cross-sectional study. SETTING: Two population-based studies, the Women's Health and Aging Studies I and II, Baltimore, Maryland. PARTICIPANTS: Six hundred thirty-three community-dwelling women aged 70 to 80 with Hb levels obtained within 90 days from baseline assessment. MEASUREMENTS: Mobility difficulty (self-reported difficulty walking one-quarter of a mile or climbing 10 steps (primary outcome)). SPS, a performance-based summary measure of lower extremity function that combines the results of walking, chair stands, and balance tests (secondary outcome). RESULTS: Mobility difficulty prevalence was not constant within the WHO "normal" Hb range (12.0-16.0 g/dL). For example, a Hb of 13.5 g/dL was associated with a significantly lower mobility difficulty prevalence than a Hb of 12.0 g/dL (OR=0.68, 95% CI=0.47-0.93), even after adjustment for chronic diseases and other relevant health indicators. A consistent trend of improvement in performance-based scores with increasing Hb categories less than 12.0 g/dL, 12.0 to 13.0g/dL, and 13.0-14.0 g/dL was observed. CONCLUSION: Our findings raise two hypotheses: (1) Hb currently perceived as "mildly-low" and even "low-normal" might have an independent, adverse effect on mobility function, and (2) Hb of 12.0 g/dL might be a suboptimal criterion for defining anemia in older women. Formal testing of these hypotheses might prove relevant for anemia- and mobility disability-related clinical decision-making.
OBJECTIVES: The World Health Organization (WHO) and other currently used criteria for defining anemia in older women are mainly based on statistical distribution considerations. To explore their clinical appropriateness, we evaluated the relationship between hemoglobin (Hb) concentration, prevalent mobility difficulty, and the Summary Performance Score (SPS). DESIGN: Cross-sectional study. SETTING: Two population-based studies, the Women's Health and Aging Studies I and II, Baltimore, Maryland. PARTICIPANTS: Six hundred thirty-three community-dwelling women aged 70 to 80 with Hb levels obtained within 90 days from baseline assessment. MEASUREMENTS: Mobility difficulty (self-reported difficulty walking one-quarter of a mile or climbing 10 steps (primary outcome)). SPS, a performance-based summary measure of lower extremity function that combines the results of walking, chair stands, and balance tests (secondary outcome). RESULTS: Mobility difficulty prevalence was not constant within the WHO "normal" Hb range (12.0-16.0 g/dL). For example, a Hb of 13.5 g/dL was associated with a significantly lower mobility difficulty prevalence than a Hb of 12.0 g/dL (OR=0.68, 95% CI=0.47-0.93), even after adjustment for chronic diseases and other relevant health indicators. A consistent trend of improvement in performance-based scores with increasing Hb categories less than 12.0 g/dL, 12.0 to 13.0g/dL, and 13.0-14.0 g/dL was observed. CONCLUSION: Our findings raise two hypotheses: (1) Hb currently perceived as "mildly-low" and even "low-normal" might have an independent, adverse effect on mobility function, and (2) Hb of 12.0 g/dL might be a suboptimal criterion for defining anemia in older women. Formal testing of these hypotheses might prove relevant for anemia- and mobility disability-related clinical decision-making.
Authors: Bryan J McCranor; Jacqueline M Langdon; Olivier D Prince; Laurette K Femnou; Alan E Berger; Chris Cheadle; Curt I Civin; Airie Kim; Seth Rivera; Tomas Ganz; Sophie Vaulont; Qian-Li Xue; Jeremy D Walston; Cindy N Roy Journal: Haematologica Date: 2013-08-30 Impact factor: 9.941
Authors: Paulo H M Chaves; Michelle C Carlson; Luigi Ferrucci; Jack M Guralnik; Richard Semba; Linda P Fried Journal: J Am Geriatr Soc Date: 2006-09 Impact factor: 5.562
Authors: Elizabeth Price; Andrew S Artz; Huiman Barnhart; Shelly Sapp; Gordon Chelune; William B Ershler; Jeremy D Walston; Victor R Gordeuk; Nathan A Berger; David Reuben; Josef Prchal; Sunil V Rao; Cindy N Roy; Mark A Supiano; Stanley L Schrier; Harvey Jay Cohen Journal: Blood Cells Mol Dis Date: 2014-07-25 Impact factor: 3.039
Authors: Linda P Fried; Qian-Li Xue; Anne R Cappola; Luigi Ferrucci; Paulo Chaves; Ravi Varadhan; Jack M Guralnik; Sean X Leng; Richard D Semba; Jeremy D Walston; Caroline S Blaum; Karen Bandeen-Roche Journal: J Gerontol A Biol Sci Med Sci Date: 2009-06-30 Impact factor: 6.053
Authors: C Barrett Bowling; Paul Muntner; Brian D Bradbury; Ryan D Kilpatrick; John J Isitt; Amy H Warriner; Jeffrey R Curtis; Suzanne Judd; Cynthia J Brown; Richard M Allman; David G Warnock; William McClellan Journal: Am J Med Sci Date: 2013-06 Impact factor: 2.378
Authors: L Jørgensen; T Skjelbakken; M-L Løchen; L Ahmed; A Bjørnerem; R Joakimsen; B K Jacobsen Journal: Osteoporos Int Date: 2009-12-03 Impact factor: 4.507